Date | Price Target | Rating | Analyst |
---|---|---|---|
11/20/2023 | Underweight | JP Morgan | |
10/25/2023 | $3.00 → $1.00 | Buy → Hold | Jefferies |
1/6/2023 | $1.30 → $3.00 | Hold → Buy | Jefferies |
5/6/2022 | Neutral → Underweight | JP Morgan | |
5/5/2022 | $10.00 → $3.00 | Outperform → Mkt Perform | SVB Leerink |
5/5/2022 | $10.00 → $3.00 | Buy → Neutral | H.C. Wainwright |
5/4/2022 | Outperform → Market Perform | Northland Capital | |
2/16/2022 | $11.00 → $10.00 | Outperform | SVB Leerink |
SC 13G/A - AMARIN CORP PLC\UK (0000897448) (Subject)
SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)
SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)
JP Morgan resumed coverage of Amarin with a rating of Underweight
Jefferies downgraded Amarin from Buy to Hold and set a new price target of $1.00 from $3.00 previously
Jefferies upgraded Amarin from Hold to Buy and set a new price target of $3.00 from $1.30 previously
Aris Mining Corporation (Aris Mining or the Company) (TSX:ARIS) (NYSE-A: ARMN) announces gold production of 99,983 ounces for the first half of 2024 (H1 2024), with 88,613 ounces from Segovia and 11,370 ounces from the Marmato Upper Mine. In the same period in 2023, the Company produced 104,906 ounces of gold, including 94,395 ounces from Segovia and 10,511 ounces from the Marmato Upper Mine. As the Segovia mine plan progresses to higher-grade zones the Company is on track to meet the lower end of its full-year production guidance of 220,000 to 240,000 ounces.Neil Woodyer, CEO of Aris Mining, commented "Our Segovia processing facilities performed well during Q2, consistently achieving over 2
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new supported and/or funded research on the clinical impact of VASCEPA®/VAZKEPA (icosapent ethyl) in patients with diabetes and high cardiovascular risk and the anti-Lp(a) oxidation mechanistic effects of eicosapentaenoic acid (EPA) will be presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting September 9 – 13, 2024 in Madrid, Spain. The two accepted abstracts, which will be presented by international academic collaborators who have partnered with Amarin, include: A post-hoc analysis from the REDUCE-IT trial examining the
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT® cardiovascular outcomes trial with VASCEPA®/VAZKEPA® (icosapent ethyl), as well as abstracts showcasing the mechanistic activity of eicosapentaenoic acid (EPA) that will be presented at the European Society of Cardiology (ESC) Congress in London, United Kingdom, August 30 – September 2, 2024. The accepted abstracts include a REDUCE-IT subgroup analysis to assess if baseline small dense low density lipoprotein cholesterol (sdLDL-C) modifies the effect of icosapent ethyl (IPE) on cardiovascular ev
-- Cash Position of $307 Million Provides Stable and Strong Capital Foundation –-- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize VASCEPA/VAZKEPA Performance Globally -- -- Leadership Transition Completed with Appointment of Aaron Berg as President and CEO -- DUBLIN and BRIDGEWATER, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today reported financial results for the second quarter ended June 30, 2024, and provided a business update. Commenting on the Company, Aaron Berg, Amarin's President and CEO, said, "As I begin in my new role as CEO of Amarin, my focus is clear: drive value by focusing on
-- Cash Position of $307 Million Provides Stable and Strong Capital Foundation –-- Total Net Revenue of $68 Million ($124 Million Year-To-Date) Reflecting Continuing Efforts to Maximize VASCEPA/VAZKEPA Performance Globally -- -- Leadership Transition Completed with Appointment of Aaron Berg as President and CEO -- DUBLIN and BRIDGEWATER, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today reported financial results for the second quarter ended June 30, 2024, and provided a business update. Commenting on the Company, Aaron Berg, Amarin's President and CEO, said, "As I begin in my new role as CEO of Amarin, my focus is clear: drive value by focusing on
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its second quarter 2024 results followed by Q&A on Wednesday, July 31st, 2024, at 8:00 a.m. ET. The conference call with management will follow the release of the Company's second quarter 2024 financial results in the pre-market hours on July 31st. To enhance engagement with the company's shareholder base and facilitate connections with its investors, Amarin is partnering with Say Technologies to allow shareholders to submit and upvote questions
-- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 ‘24 versus Q4 ‘23 Driven by Spain and the UK-- -- Current Cash Position of $308 Million; Remains Stable Over Seven Quarters -- -- Share Repurchase Program of up to $50 Million Approved by Shareholders; Repurchases Expected to Commence Following UK High Court Approval in Second Quarter 2024 -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN, Ireland and BRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today provided an update on the Company'
-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as President & CEO of the Company. "On behalf of the Company's Board of Directors, I thank Pat for his contributions to Amarin, and I welcome working closely again with Aaron
DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting (AGM). Importantly, shareholders approved each of the two proposals required for the Company to proceed with its previously announced intent to pursue a share repurchase program of up to $50 million. This permits the Company to request U.K. High Court approval, as required under U.K. company law, and if approved by the U.K. High Court, commence the share repurchase program by the end of the second quarter of 2024. As part of the Annual General Meeting, shareholders
-- Provoost Brings More than 20 Years of Corporate Counsel Experience to Amarin -- DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Jonathan Provoost as the Company's new Executive Vice President, Chief Legal & Compliance Officer. He will join the Company on November 15. Mr. Provoost, who most recently served as Vice President, General Counsel and Chief Compliance Officer at Tris Pharma, Inc., brings more than 20 years of corporate legal experience, having served most of his career in large and medium-sized pharmaceutical companies. "We are excited to welcome Jonathan to Amarin, where he will
4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
8-K - AMARIN CORP PLC\UK (0000897448) (Filer)
10-Q - AMARIN CORP PLC\UK (0000897448) (Filer)
8-K - AMARIN CORP PLC\UK (0000897448) (Filer)